乌帕替尼与托法替布治疗溃疡性结肠炎的一年比较有效性:多中心队列研究
这项回顾性多中心队列研究比较了乌帕替尼与托法替布治疗溃疡性结肠炎52周的无激素临床缓解和內镜下应答/缓解。共155例患者起始乌帕替尼(n=81;30%既往托法替布暴露)或托法替布(n=74;0%既往乌帕替尼暴露)。经逆概率治疗加权逻辑回归后,乌帕替尼相比托法替布与显著更高的无激素临床缓解几率相关(OR 3.01,95%CI 1.39-6.55),內镜下应答/缓解无差异。
要点
- 乌帕替尼组52周无激素临床缓解几率显著高于托法替布组(OR 3.01,95%CI 1.39-6.55)。
- 乌帕替尼与托法替布在52周內镜下应答/缓解方面无差异。
- 乌帕替尼组30%有既往托法替布暴露,托法替布组0%有既往乌帕替尼暴露。
核心结论
- 乌帕替尼在溃疡性结肠炎52周时实现无激素临床缓解方面比托法替布更有效。
研究设计与样本
- 回顾性多中心队列研究,比较成人溃疡性结肠炎患者起始乌帕替尼或托法替布后52周的无激素临床缓解和內镜下应答/缓解。
- 共155例患者,乌帕替尼组81例(30%有既往托法替布暴露),托法替布组74例(0%有既往乌帕替尼暴露)。
- 采用逆概率治疗加权逻辑回归进行分析。
主要发现
- 经逆概率治疗加权逻辑回归后,乌帕替尼相比托法替布与显著更高的无激素临床缓解几率相关(OR 3.01,95%CI 1.39-6.55)。
- 乌帕替尼与托法替布在內镜下应答/缓解方面无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. RESULTS: A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. DISCUSSION: Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.
引用
- Dalal RS, Kallumkal G, Cabral HJ, et al. One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study. Am J Gastroenterol. 2024. PMID: 38470031. doi:10.14309/ajg.0000000000002746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。